Serum fibrosis scores as predictors of liver fibrosis and long-term outcomes in metabolic dysfunction-associated steatotic liver disease, including cirrhosis
Revista de Investigación Clínica · 2025
DOI: 10.1016/j.ric.2025.100016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista de Investigación Clínica, 2025. Verfasst von Toprak Koçak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Dokuz Eylul University Hospital, Izmir 35000, Turkey. Hauptthemen laut MEDLINE: Liver Cirrhosis, Fatty Liver. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is commonly linked to liver fibrosis, which may progress to cirrhosis. FIB-4, APRI, and NFS are used to predict fibrosis severity, but their accuracy and role in long-term outcomes remain unclear. OBJECTIVES: This study evaluates the predictive value of these scores for fibrosis and assesses the incidence of de novo cirrhosis and survival outcomes in MASLD patients. METHODS: This retrospective, single-center study included 175 MASLD patients in our university medical center. The diagnostic performance of FIB-4, APRI, and NFS for advanced fibrosis (stage 3-4) was assessed using receiver operating characteristic (ROC) analysis. Cox regression analysis was performed to evaluate factors associated with de novo cirrhosis and survival outcomes. RESULTS: The mean age was 49.9±14.1 years, and 54.9% were female. The median follow-up was 78 months. ROC analysis showed FIB-4 (AUC: 0.77) was the best predictor of advanced fibrosis, followed by APRI (AUC: 0.74) and NFS (AUC: 0.74). Multivariate analysis identified fibrosis stage (HR: 3.045, p=0.001) and hypertension (HR: 4.096, p=0.047) as independent predictors of de novo cirrhosis. Age (HR: 1.070, p=0.031), albumin (HR: 15.151, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Dokuz Eylul University Hospital, Izmir 35000, Turkey.
- Department of Gastroenterology, Dokuz Eylul University Hospital, Izmir 35000, Turkey.
- Department of Internal Medicine, Dokuz Eylul University Hospital, Izmir 35000, Turkey. Electronic address: huseyin.dongelli@deu.edu.tr.
- Department of Pathology, Dokuz Eylul University Hospital, Izmir 35000, Turkey.
Zitieren
APA
Koçak, T., Danış, N., Döngelli, H., Aysal Ağalar, A., Bengi, G., & Akarsu, M. (2025). Serum fibrosis scores as predictors of liver fibrosis and long-term outcomes in metabolic dysfunction-associated steatotic liver disease, including cirrhosis. Revista de Investigación Clínica. https://doi.org/10.1016/j.ric.2025.100016
Vancouver
Koçak T, Danış N, Döngelli H, Aysal Ağalar A, Bengi G, Akarsu M. Serum fibrosis scores as predictors of liver fibrosis and long-term outcomes in metabolic dysfunction-associated steatotic liver disease, including cirrhosis. Revista de Investigación Clínica. 2025. doi:10.1016/j.ric.2025.100016
BibTeX
@article{Koak2025,
author = {Koçak, Toprak and Danış, Nilay and Döngelli, Hüseyin and Aysal Ağalar, Anıl and Bengi, Goksel and Akarsu, Mesut},
title = {Serum fibrosis scores as predictors of liver fibrosis and long-term outcomes in metabolic dysfunction-associated steatotic liver disease, including cirrhosis},
journal = {Revista de Investigación Clínica},
year = {2025},
doi = {10.1016/j.ric.2025.100016}
}
EUVIMED